Navigation Links
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
Date:2/19/2008

, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

For Further Information, Please Contact:

UCB

Antje Witte, Vice-President, Corporate Communications and Investor Relations
Phone: +32.2.559.9414,

antje.witte@ucb-group.com

Eric Miller, Director, U.S. Corporate Communications and Public Relations

Phone: 770-970-8569

eric.miller@ucb-group.com

sanofi-aventis

Susan Brooks, US Communications

Phone: 908-981-6566 Mobile: 201-572-4994

Email: Susan.Brooks@sanofi-aventis.com

XYZAL(R) is a trademark of UCB Group of companies.


'/>"/>
SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
9. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
10. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
11. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... from a Phase 1/2 study of perifosine in combination ... from or refractory to bortezomib , ... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced ... combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory ...
... SOUTH SAN FRANCISCO, Calif., Dec. 9 Portola,Pharmaceuticals, ... advances in cardiovascular disease, inflammatory disease,and cancer, today ... a large Phase II clinical trial of PRT060128, ... undergoing non-urgent,percutaneous coronary intervention (PCI). , ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 7Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 2Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 3
(Date:8/22/2014)... stenting to open blockages in the kidney arteries ... from modern clinical trials, according to new recommendations ... and Cardiovascular Interventions today by the Society ... Hospitals Case Medical Center,s Sahil Parikh, MD, Director, ... Case Western Reserve University School of Medicine was ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Counseling may do little to ... finds. Researchers analyzed 66 studies that included nearly ... at high risk for drinking problems. Participants in 49 ... in the rest of the studies attended group sessions ... A counseling technique called motivational interviewing was used in ...
(Date:8/22/2014)... A new, online conference is coming August 25th-29th, 2014 about ... open to everyone. Over 20 top experts will be ... how to stop emotional eating, start eating healthier and successful ... not a diet. The concept is about how to make ... don't eat that" approach. , You can sign up for ...
(Date:8/22/2014)... 22, 2014 Key West Health & ... revealed their much anticipated study results of the 12 ... and released an accompanying infographic on their website. It ... have a major impact on the skin and contribute ... more. , When asked how they determined the results, ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:20 Top Experts Discuss How to Unravel the Food-Mood Connection 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3
... , FRIDAY, April 27 (HealthDay News) -- Two genetic ... as primary open-angle glaucoma, according to new research. Glaucoma ... U.S. National Eye Institute said in a news release. ... worldwide, is due to irreversible damage to the optic nerve," ...
... the structure of a key part of the human obesity ... which could help provide new treatments for the complications of ... in the journal Structure , will greatly enhance the ... the receptor for the obesity hormone leptin. This could have ...
... , FRIDAY, April 27 (HealthDay News) -- Children who are bullied ... time they are 12 years old, according to a new study. ... the United Kingdom said its findings, published online April 27 in ... for this type of behavior. Examples of self-harming behaviors ...
... 5th Annual Jean Sindab Triple Negative Breast Cancer ... Emory University, provides an intimate learning environment in ... cancers (TNBC) will be explored. Nationally recognized speakers ... on current research in TNBC. TNBC affects young ...
... the discovery of small molecules that kill cancer cells ... results, in both cell and mouse models, demonstrate that ... by viral proteins, thus killing the infected tumor cells. ... April 20 issue of the journal Chemistry & ...
... ATLANTA April 26, 2012 New guidelines from ... a healthy weight, getting adequate physical activity, and eating ... and increase the likelihood of disease-free survival after a ... and Physical Activity Guidelines for Cancer Survivors, published early ...
Cached Medicine News:Health News:Research Gets Closer to Genetic Roots of Glaucoma 2Health News:New drug to tackle fat problems 2Health News:Bullied Children at Greater Risk for Self-Harm, Study Finds 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 2Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: